Physician profile
Kirk E Kanady
NPI 1720089451
$3,130.40
in general payments reported to CMS, 2019-2025
31 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $183 · 2021: $344 · 2022: $657 · 2023: $290 · 2024: $264 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,151.40 | 2019-2024 | Spaceoar Vue System - 10ml, Spaceoar System |
| Progenics Pharmaceuticals, INC. | $304.48 | 2022-2025 | Pylarify |
| Janssen Biotech, INC. | $159.10 | 2019 | |
| Covidien LP | $139.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $130.90 | 2019-2025 | Imfinzi |
| Blue Earth Diagnostics | $129.19 | 2019-2025 | Posluma |
| Emd Serono, INC. | $101.86 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $93.60 | 2021-2024 | Prolaris |
| Novartis Pharmaceuticals Corporation | $88.93 | 2019-2025 | |
| Celgene Corporation | $85.83 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $69.95 | 2019-2025 | Libtayo |
| Tactile Systems Technology INC | $69.08 | 2021-2023 | Entre Plus, Flexitouch Plus |
| Teleflex LLC | $66.49 | 2024-2025 | Barrigel |
| Palette Life Sciences, INC. | $55.96 | 2022 | |
| Eisai INC. | $54.01 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verastem, INC. | $53.23 | 2019 | |
| Telix Pharmaceuticals | $52.35 | 2024-2025 | Illuccix |
| Myovant Sciences INC. | $43.78 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.35 | 2019-2020 | |
| Genzyme Corporation | $30.69 | 2019 | |
| Amgen INC. | $29.39 | 2020 | |
| Medtronic USA, INC. | $21.25 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $20.77 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.76 | 2019 | |
| Merck Sharp & Dohme LLC | $19.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.84 | 2020 | |
| Seagen INC. | $18.23 | 2020 | |
| Astellas Pharma US INC | $18.01 | 2019 | |
| Lilly USA, LLC | $17.44 | 2019 | |
| Exelixis INC. | $17.38 | 2019 | |
| Dova Pharmaceuticals | $15.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Kanady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.